Expert: Marboxlovir has not been approved for prophylaxis and anti-flu treatment should not rely on “star drugs”

On January 17th, 2025, the National Health Committee held a press conference to introduce the relationship between the current solar terms and health, and to answer questions from reporters.

Li Tong, a chief physician at Beijing You’an Hospital, stated at the meeting that Maralaxavir has recently gained popularity online. Currently, our country has only approved Maralaxavir for the treatment of influenza, and has not yet approved its use for post-exposure prophylaxis. When using Maralaxavir to treat influenza, the following points should be noted:

First, antiviral drugs should be used as early as possible. We recommend using them within 48 hours of onset to achieve better results.

Second, Maralaxavir is currently only approved for antiviral therapy in people aged 5 and above in our country. Children under 5 years old should still use Oseltamivir for influenza treatment. There is also limited data on the use of Maralaxavir in pregnant and lactating women, so pregnant and lactating women should still choose Oseltamivir for antiviral therapy.

Third, when Maralaxavir is used in combination with other drugs, there may be some interactions. If you need to use this drug, be sure to inform your doctor about other drugs you are currently using, including non-prescription drugs and supplements, to avoid drug interactions.

Fourth, if you experience allergy symptoms such as rash, itching, or difficulty breathing during drug use, or other severe discomforts, stop taking the drug immediately and seek medical attention.

Li Tong reminded everyone not to迷信 overly certain “star drugs” for influenza treatment. The scientific use of targeted drugs and sufficient rest are helpful for faster recovery.

You May Have Missed